Alexandria Venture Investments
No summary available yet.
This is the definition of corporate VC done right - except it's not really VC, it's real estate empire building with a science twist. Alexandria's secret sauce isn't just their money (they have plenty as a public REIT), it's that they own the buildings where biotech companies live and breathe. When they invest in you, they're betting you'll become their tenant, creating a beautiful conflict of interest that somehow works for everyone. They're one of the most prolific investors in the corporate VC space, but founders should know this isn't your typical Sand Hill Road partnership - they're thinking decades, not quick flips, which can be great for patient capital but frustrating if you need nimble decision-making.
- —Best for: Biotech companies wanting patient capital plus world-class lab space in top clusters
- —Watch out for: They're landlords first, VCs second - expect real estate considerations in every deal
- —Known for: Deep life science expertise, massive check sizes, and owning half of Kendall Square
Since its inception in 1996, Alexandria has invested in disruptive life science companies that are advancing transformative new modalities, platforms, and innovative medicines to meaningfully improve human health. Alexandria Venture Investments primarily invests in biotech and healthcare startups, with a focus on pharmaceuticals and leverages its experience and in-depth understanding of the life science and technology industries.
Alexandria focuses primarily on Series A rounds with an average of $150M and Series C rounds averaging $97.2M, plus some Seed investments averaging $10M. Their investments span Life Sciences to High Tech and Food and Agriculture Tech, with 9 Life Sciences investments being their top sector focus.
CEO since July 2022 and CIO since September 2023, previously Co-CEO from 2018-2022. Has been with Alexandria since 1998 in various capacities. Economics degree from UCLA with deep real estate background.
Promoted to EVP in January 2026, has been with Alexandria since 2014. Master's in biotechnology from Columbia and summa cum laude cognitive neuroscience from UPenn. Recognized in Crain's 40 Under 40 and Global Corporate Venture Powerlist since 2022.
Listed as Co-Chief Investment Officer and Regional Market Director for San Diego, but specific background details are limited in public sources.
Have a specific question about Alexandria Venture Investments?
Ask Bernie →